These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22687700)

  • 1. [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
    Motohashi S; Hori K; Ono T; Ohnishi K; Kawakami J
    Yakugaku Zasshi; 2012; 132(5):675-81. PubMed ID: 22687700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial.
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Kimura M; Taguchi T; Yoshida T; Nagao J; Sakuma Y; Toth G
    Int J Clin Oncol; 2009 Aug; 14(4):337-43. PubMed ID: 19705245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
    Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus injection].
    Tsudo M; Moriguchi T
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1747-53. PubMed ID: 9757201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
    Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
    J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
    Goto T; Tanimoto K; Ishibashi M; Okamura S
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study.
    Moreno J; Sahade M; del Giglio A
    Support Care Cancer; 2005 Oct; 13(10):850-3. PubMed ID: 15838618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Cabanillas Stanchi KM; Vek J; Schlegel P; Rupprecht JV; Flaadt T; Weber S; Michaelis S; Lang P; Handgretinger R; Döring M
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):1089-1100. PubMed ID: 32056007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
    Uchida M; Ikesue H; Kato K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Egashira N; Akashi K; Oishi R
    Am J Health Syst Pharm; 2013 Feb; 70(4):343-9. PubMed ID: 23370141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer R; Fitts D
    J Clin Oncol; 1994 Oct; 12(10):2204-10. PubMed ID: 7931490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
    Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
    Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.